REFERENCES
- Krause K H, Krause J, Magyarosy I. Comorbidity of fibromyalgia syndrome and attention deficit hyperactivity disorder-possible implications for the therapy of fibromyalgia syndrome. Eur J Phys Med Rehab 1997; 7(147)
- Diagnostic and statistical manual of mental disorders, 4th ed. American Psychiatric Press, Washington, DC 1994; 78–85
- Wender P H. Attention-deficit hyperactivity disorder in adults. Oxford University Press, New York, Oxford 1995
- Hechtman L, Weiss G, Perlman T. Hyperactives as young adults: Past and current substance abuse and antisocial behavior. Am J Orthopsychiatry 1984; 54: 415–425
- Weiss G, Hechtman L T, Milroy T, Perlman T. Psychiatric status of hyperactives as adults: A controlled prospective 15-year follow-up of 63 hyperactive children. J Amer Acad Child Psychiatry 1985; 24: 211–220
- Ward M F, Wender P H, Reimherr F W. The Wender Utah Rating Scale: An aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry 1993; 150: 885–890
- Conners C K. Rating scales for use in drug studies with children. Psychopharmacol Bull 1973; 9: 24–84
- Brown T E. Brown attention deficit disorder scales. The Psychological Corporation, San Antonio, TX 1996
- Quinn P O. Neurobiology of attention disorder. A comprehensive guide to attention deficit disorder in adults., K G Nadeau. Brunner/Mazel, New York 1995; 18–34
- Wilens T E, Biederman J, Spencer T J, Prince J. Pharmacotherapy of adult attention deficit/hyperactivity disorder: A review. J Clin Psychopharmacol 1995; 15: 270–279
- Trott G E, Friese H J, Menzel M, Nissen G. Use of moclobemide in children with attention deficit hyperactivity disorder. Psychopharmacology 1992; 106: S134–R136
- Bhagauan H N, Coleman M, Coursina D B. The effect of pyridoxine hydrochloride on blood serotonin and pyridoxal phosphate contents in hyperactive children. Pediatrics 1975; 55: 437–441
- Coleman M. Serotonin concentrations in whole blood of hyperactive children. J Pediat 1971; 78: 989–990
- Crofford L J. The hypothalamic-pituitary-adrenal stress axis in the fibromyalgia syndrome. J Musculoske Pain 1996; 4(1/2)181–200
- Russell I J. Neurochemical pathogenesis of fibromyalgia syndrome. J Musculoske Pain 1996; 4(1/2)61–92
- McCain G A. A clinical overview of the fibromyalgia syndrome. J Musculoske Pain 1996; 4(1/2)9–34
- Krause K H, Krause J. Use of MAO-A inhibitor moclobemide in fibromyalgia syndrome-First clinical results. Eur Neuropsychopharmacol 1997; 7(Suppl 2)S274